Get the Stockscreener App
0.00
100.00%
-76.01
Hologic Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
See More
Previous Close:
$76.01
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$16.97B
Revenue:
$4.13B
Net Income/Loss:
$543.90M
P/E Ratio:
0.00
EPS:
2.41
Net Cash Flow:
$957.20M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$76.07
Hologic Inc Stock (HOLX) Company Profile
Name
Hologic Inc
Sector
Industry
Phone
(508) 263-2900
Address
250 CAMPUS DRIVE, MARLBOROUGH, MA
Compare HOLX vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOLX
Hologic Inc
|
0.00 | 16.97B | 4.13B | 543.90M | 957.20M | 2.41 |
ISRG
Intuitive Surgical Inc
|
411.06 | 146.23B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
146.24 | 40.60B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
66.85 | 32.44B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
36.61 | 31.40B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
194.78 | 27.91B | 5.54B | 1.52B | 1.74B | 10.37 |
Hologic Inc Stock (HOLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-26 | Downgrade | Argus | Buy → Hold |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-21-25 | Downgrade | BNP Paribas Exane | Outperform → Neutral |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-18-25 | Upgrade | Argus | Hold → Buy |
| Aug-06-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-27-25 | Reiterated | Needham | Hold |
| Mar-03-25 | Downgrade | Argus | Buy → Hold |
| Feb-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-03-25 | Downgrade | Needham | Buy → Hold |
| Dec-13-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-10-24 | Initiated | Jefferies | Hold |
| Dec-10-24 | Reiterated | Needham | Buy |
| Oct-01-24 | Downgrade | Citigroup | Buy → Neutral |
| Jun-27-24 | Initiated | Stephens | Overweight |
| Apr-03-24 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-23 | Upgrade | Needham | Hold → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jul-20-22 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-20-22 | Initiated | UBS | Neutral |
| Jul-18-22 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-04-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Oct-14-21 | Initiated | Redburn | Neutral |
| Jul-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-20-20 | Downgrade | Needham | Buy → Hold |
| Nov-05-20 | Reiterated | Needham | Buy |
| Jun-30-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-03-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-30-20 | Reiterated | Needham | Buy |
| Apr-30-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Apr-07-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-13-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-01-19 | Reiterated | Needham | Buy |
| May-02-19 | Reiterated | Needham | Buy |
| Jan-31-19 | Reiterated | Needham | Buy |
| Jan-02-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-09-18 | Initiated | UBS | Neutral |
| Sep-13-18 | Downgrade | BofA/Merrill | Buy → Neutral |
View All
Hologic Inc Stock (HOLX) Latest News
Hologic Stock (US4364401012): Valuation Metrics Under the Microscope - AD HOC NEWS
First Trust Merger Arbitrage Fund's Hologic Inc(HOLX) Holding History - GuruFocus
Siemens ordered to recall mammography device across European countries - Life Sciences Intellectual Property Review
Life After Breast Cancer: Why Treatment Decisions Are Becoming More Personal - Hologic
· Analyst Forecast - MLQ.ai
T-Score & DXA: How Hologic Helped Define Bone Health - Hologic
Hologic CEO Steve MacMillan to retire as go-private deal closes - Investing.com
BlackRock Event Driven Equity Fund's Hologic Inc(HOLX) Holding History - GuruFocus
Newly Published Data Suggests AI’s Potential to Help Streamline Mammography Reviews While Maintaining High Effectiveness in Finding Cancer - Hologic
GABELLI & Co INVESTMENT ADVISERS, INC.'s Hologic Inc(HOLX) Holding History - GuruFocus
Hologic, Inc. (HOLX) Stock Analysis: Navigating Modest Growth And Strategic Stability - DirectorsTalk Interviews
Hologic's BCI test shows growing impact in endocrine therapy decisions - MSN
Hologic to Present New Data at ASCO 2026 Demonstrating the Clinical Impact of the Breast Cancer Index® Test on Extended Endocrine Therapy Decisions - BioSpace
Hologic to Present New Data at ASCO 2026 Demonstrating the Clinical Impact of the Breast Cancer Index - Business Wire
Hologic, Inc. (HOLX) Stock Analysis: Navigating Steady Growth In The Healthcare Sector - DirectorsTalk Interviews
OCONNOR, A Distinct Business Unit Of UBS ASSET MANAGEMENT AMERICAS (LLC) HOLX Holdings History - GuruFocus
Absolute Gestao de Investimentos Ltda.'s Hologic Inc(HOLX) Holding History - GuruFocus
The Official Home of the Women's Tennis Association | WTA Tennis - WTA Tennis
Hologic, Inc. (HOLX) Stock Analysis: Steady Growth With A Strong Focus On Women's Health - DirectorsTalk Interviews
CIBRA Capital Ltd's Hologic Inc(HOLX) Holding History - GuruFocus
How Data Can Serve as a Lifeline for Women’s Health - Hologic
Laura Friedman from California’s 30th District makes transactions in Hologic, Inc. - Investing.com Nigeria
Laura Friedman from California’s 30th District makes transactions in Hologic, Inc. By Investing.com - Investing.com South Africa
Investors heavily search Hologic, Inc. (HOLX): Here is what you need to know - MSN
Hologic stock (US4364401012): Analyst hold consensus with limited upside - AD HOC NEWS
Hologic, Inc. (HOLX) is a trending stock: Facts to know before betting on it - MSN
Hologic stock (US4364401012): Blackstone and TPG acquisition nears completion - AD HOC NEWS
Hologic Tells NH Justices It's One Org.; State Pushes Back - Law360
Body Composition Analyzers Market is expected to Hit US$ 1.25 - openPR.com
Hologic stock (US4364401012): Joins S&P SmallCap 600 ahead of May 14 - AD HOC NEWS
New Hampshire Justices Dissect Hologic’s Business Tax Method - Bloomberg Law News
Human Papillomavirus Testing Market Witnesses Asia-Pacific & North America Growth | Roche, Qiagen, Hologic - openPR.com
Primary Care Poc Diagnostics Market Is Going to Boom | Cepheid, Hologic - openPR.com
OM1 Supports 650,000 Patient Real-World Regulatory Submission for FDA Approval of Hologic's Aptima HPV Assay - Business Wire
Hologic, Inc. (HOLX) Stock Analysis: Steady Growth With Limited Upside Potential - DirectorsTalk Interviews
Hologic stock (US4364401012): Takeover deal and women’s health focus in focus - AD HOC NEWS
Hereditary Cancer Testing Market Will Generate Booming Growth - openPR.com
Body Composition Analyzers Market Size Accelerating at 11.2% - openPR.com
Top medtech executive moves in 2026 - MedTech Dive
Hologic Nurse Advocate Program: Support for Heavy Periods & Fibroids - Hologic
GW&K Investment Management, LLC's Hologic Inc(HOLX) Holding History - GuruFocus
Hologic, Inc. (HOLX) Stock Analysis: Exploring the Healthcare Giant’s Strong Position with Limited Upside - DirectorsTalk Interviews
Blackstone & TPG Complete Hologic Acquisition, Appoint Joe Almeida as CEO - Digital Health News
Vanguard owns 16.7M Hologic shares in filing (HOLX) — 7.49% stake disclosed - Stock Titan
Hologic Stock (US4364401012): Earnings Release Scheduled for Today - AD HOC NEWS
MSN Money - MSN
Hologic Inc Stock (HOLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):